ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.67
0.00%
US Tech 100
19,131.60
-0.23%
S&P 500
5,477.90
0.16%
US Dollar vs CAD
1.36972
-0.06%
Bitcoin
61,105.18
0.48%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Elicio Therapeutics Inc (ELTX)

  7. Elicio Therapeutics Inc (ELTX) News

ELTX

Elicio Therapeutics (ELTX)

Elicio Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ELTX
DateTimeSourceHeadlineSymbolCompany
06/18/20247:30AMGlobeNewswire Inc.Elicio Therapeutics Reports Inducement GrantsNASDAQ:ELTXElicio Therapeutics Inc
06/11/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELTXElicio Therapeutics Inc
06/11/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELTXElicio Therapeutics Inc
06/03/20244:24PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELTXElicio Therapeutics Inc
06/03/20243:41PMEdgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ELTXElicio Therapeutics Inc
05/23/20244:30PMGlobeNewswire Inc.Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
05/15/20243:34PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
05/15/20243:30PMGlobeNewswire Inc.Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
04/25/20247:30AMGlobeNewswire Inc.Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
04/05/20243:30PMGlobeNewswire Inc.Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
03/29/20247:30AMGlobeNewswire Inc.Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
03/18/20247:00AMGlobeNewswire Inc.Elicio Therapeutics Announces $6.0 Million Private Placement FinancingNASDAQ:ELTXElicio Therapeutics Inc
02/05/20247:30AMGlobeNewswire Inc.Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ELTXElicio Therapeutics Inc
01/25/20248:00AMGlobeNewswire Inc.Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid TumorsNASDAQ:ELTXElicio Therapeutics Inc
01/17/20247:30AMGlobeNewswire Inc.Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI SymposiumNASDAQ:ELTXElicio Therapeutics Inc
01/16/20247:30AMGlobeNewswire Inc.Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:ELTXElicio Therapeutics Inc
01/11/20247:30AMGlobeNewswire Inc.Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer StudyNASDAQ:ELTXElicio Therapeutics Inc
01/09/20245:00AMGlobeNewswire Inc.Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002NASDAQ:ELTXElicio Therapeutics Inc
12/22/20238:00AMGlobeNewswire Inc.Elicio Therapeutics Announces $7.0 Million Private Placement FinancingNASDAQ:ELTXElicio Therapeutics Inc
12/04/20237:00AMGlobeNewswire Inc.Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:ELTXElicio Therapeutics Inc
11/09/20233:30PMGlobeNewswire Inc.Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
11/03/20233:30PMGlobeNewswire Inc.Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
10/11/20237:00AMGlobeNewswire Inc.Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
09/27/20234:30PMGlobeNewswire Inc.Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic CancerNASDAQ:ELTXElicio Therapeutics Inc
09/07/20237:00AMGlobeNewswire Inc.Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer VaccinesNASDAQ:ELTXElicio Therapeutics Inc
09/06/20237:00AMGlobeNewswire Inc.Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:ELTXElicio Therapeutics Inc
09/05/20237:00AMGlobeNewswire Inc.Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic CancerNASDAQ:ELTXElicio Therapeutics Inc
08/28/20237:00AMGlobeNewswire Inc.Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of BiometricsNASDAQ:ELTXElicio Therapeutics Inc
08/22/20233:30PMGlobeNewswire Inc.Elicio Therapeutics Reports Inducement GrantsNASDAQ:ELTXElicio Therapeutics Inc
08/11/20237:30AMGlobeNewswire Inc.Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ELTX

Your Recent History

BMF
INDQ24
INDQ24 - Agosto 2024
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved